Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $226.00 at Morgan Stanley

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by equities researchers at Morgan Stanley from $225.00 to $226.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target points to a potential upside of 17.93% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Bank of America lifted their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. UBS Group reaffirmed a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Needham & Company LLC boosted their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $208.60.

Jazz Pharmaceuticals Stock Up 10.2%

JAZZ stock traded up $17.81 during midday trading on Wednesday, reaching $191.64. The company had a trading volume of 1,912,962 shares, compared to its average volume of 1,029,824. The company has a 50 day moving average of $168.08 and a two-hundred day moving average of $150.27. The company has a market capitalization of $11.64 billion, a P/E ratio of -31.32, a PEG ratio of 0.93 and a beta of 0.26. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $194.83. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Insiders Place Their Bets

In related news, CAO Patricia Carr sold 4,660 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the transaction, the chief accounting officer owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their position. The SEC filing for this sale provides additional information. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of JAZZ. Hilltop National Bank bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $36,000. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $38,000. Farther Finance Advisors LLC grew its position in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares in the last quarter. Leonteq Securities AG bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at about $50,000. Finally, GoalVest Advisory LLC acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $51,000. 89.14% of the stock is owned by institutional investors.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.